2026-01-27 - Analysis Report
**Company Overview:** Merck is a global health care leader with a 126-year history dedicated to saving lives through our innovative medicines, vaccines, and animal health products.

**Return Rate Comparison:**
- Review Stock (MRK): Cumulative Return = 69.17%
- Comparison Stock (VOO): Cumulative Return = 127.58%
- **Divergence:** -58.41%

**Alpha, Beta Analysis:**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 33.0% | 15.3% | 25.0% | 0.7 | 182.1B |
| 2017-2019  | 39.0% | 15.3% | 14.0% | 0.7 | 216.8B |
| 2018-2020  | 29.0% | 24.7% | 5.0% | 0.7 | 195.0B |
| 2019-2021  | -1.0% | 24.7% | -65.0% | 0.6 | 191.4B |
| 2020-2022  | 41.0% | 22.9% | 36.0% | 0.5 | 277.1B |
| 2021-2023  | 49.0% | 19.2% | 31.0% | 0.3 | 272.3B |
| 2022-2024  | 18.0% | 25.3% | -11.0% | 0.3 | 248.5B |
| 2023-2025  | -11.0% | 40.0% | -87.0% | 0.3 | 262.9B |

**Recent Stock Price Fluctuations:**
- Close = $107.40
- Last-Market Change = -0.72 (sharp decline)
- 5-day SMA = $109.06
- 20-day SMA = $108.56
- 60-day SMA = $100.24
- The sharp decline indicates a fluctuation issue (sharp decline)

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence:**
- Market Risk Indicator (MRI) = 0.70 (Medium Investment)
- RSI = 49.89
- PPO = -0.58
- Recent (20 days) relative divergence change = -2.30 (worsening)
- 7-day Rank change = 5 (+): rank up
- 7-day Dynamic Expected Return change = 23.20 (+): improving
- Expected Return (%) = -6.40%

**Recent News & Significant Events:**
- Is Merck (MRK) Offering Value After Recent Share Price Pause And DCF Upside Signals - simplywall.st
- Merck Chooses Evolution Over Revolution - At Proposed Price, I'm Not Surprised (NYSE:MRK) - Seeking Alpha
- Merck Stock Capital Return Hits $91 Bil - Trefis
- FDA Fast-Tracks Two Merck (MRK) Drugs With Blockbuster Potential - Yahoo Finance
- Lbp Am Sa Buys 149,928 Shares of Merck & Co., Inc. $MRK - MarketBeat
- Stock Movers: Revolution, USA Rare Earth, CoreWeave - Bloomberg.com

**Analyst Opinions:**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.90 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): $116.07 / $135.00 / $83.00

**Recent Earnings Analysis:**
| Date | EPS | Revenue |
|----|---:|---:|
| 2025-11-05 | 2.32 | $17.28 B$ |
| 2025-08-05 | 1.76 | $15.81 B$ |
| 2025-05-02 | 2.01 | $15.53 B$ |
| 2024-11-06 | 1.25 | $16.66 B$ |
| 2025-11-05 | 1.25 | $16.66 B$ |
The most recent quarter (2025-11-05) shows a significant increase in EPS and revenue.

**Financial Information: Revenue and Profitability:**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.28B | 77.69% |
| 2025-06-30 | $15.81B | 77.50% |
| 2025-03-31 | $15.53B | 77.98% |
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |
The profit margin has remained relatively stable over the past year, with slight decreases in some quarters.

**Financial Information: Capital and Profitability:**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.85B | 11.16% |
| 2025-06-30 | $48.99B | 9.04% |
| 2025-03-31 | $48.34B | 10.51% |
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |
The equity has increased steadily, and the ROE has shown improvement over the past year.

**Comprehensive Analysis (Summary of previous items):**
- The cumulative return of MRK is lower than that of VOO, indicating a divergence of 58.41%.
- The company's CAGR, MDD, Alpha, and Beta have shown fluctuations over the years, with some strong performance but also some weak periods.
- The recent stock price fluctuations indicate a sharp decline, and the RSI and PPO indicators show that the stock is slightly oversold.
- The analysis of earnings and financial information shows a stable profit margin and improving ROE over the past year.
- The analyst opinions are mostly positive, recommending a "Buy" with a target price range.
- Considering the news and significant events, it appears that Merck is undergoing various developments and has received positive news.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.